Abstract
Between 1973 and 1977, 247 patients with malignant teratoma have been treated in two units in London. Seventeen have developed brain metastases, an overall incidence of 6.2%. The median survival from diagnosis of cerebral metastases is 6 weeks and all patients except one have died. The survivor is disease-free 12 months after completing treatment, which included extensive use of chemotherapy, surgery and radiotherapy. Serum gonadotrophin (HCG) and alpha-foetoprotein (AFP) estimations have been performed in 264 patients as a means of monitoring the effects of therapy. In 42 patients (37 of whom had Stage IV disease) the peak HCG level was greater than 10(4) iu/l, and the incidence of brain metastases in this group was 26%, significantly higher than in the group with HCG levels below 10(4) iu/l, for which the incidence of cerebral deposits was 1.8% (P less than 0.0001). No significant correlation was seen between peak AFP levels and the incidence of brain metastasis. With the aim of improving results by earlier diagnosis, cerebrospinal fluid (CSF) specimens have been examined for HCG and AFP levels in 56 subjects, 9 of whom had brain metastases. A serum: CSF HCG ratio less than 40 is an accurate indication of the presence of brain metastases, and may have considerable predictive value. However, false-negative serum: CSF HCG rations (greater than 40) frequently occur in patients with proven brain deposits. Estimation of AFP in spinal fluid has not contributed to the early diagnosis of brain metastases in malignant teratoma.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bagshawe K. D., Harland S. Immunodiagnosis and monitoring of gonadotrophin-producing metastases in the central nervous system. Cancer. 1976 Jul;38(1):112–118. doi: 10.1002/1097-0142(197607)38:1<112::aid-cncr2820380120>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
- Kardana A., Bagshawe K. D. A rapid, sensitive and specific radioimmunoassay for human chorionic gonadotrophin. J Immunol Methods. 1976;9(3-4):297–305. doi: 10.1016/0022-1759(76)90204-0. [DOI] [PubMed] [Google Scholar]
- Kohn J., Orr A. H., McElwain T. J., Bentall M., Peckham M. J. Serum-alpha1-fetoprotein in patients with testicular tumours. Lancet. 1976 Aug 28;2(7983):433–436. doi: 10.1016/s0140-6736(76)92524-1. [DOI] [PubMed] [Google Scholar]
- LATERRE E. C., HEREMANS J. F., CARBONARA A. IMMUNOLOGICAL COMPARISON OF SOME PROTEINS FOUND IN CEREBROSPINAL FLUID, URINE AND EXTRACTS FROM BRAIN AND KIDNEY. Clin Chim Acta. 1964 Sep;10:197–209. doi: 10.1016/0009-8981(64)90136-6. [DOI] [PubMed] [Google Scholar]
- Lange P. H., McIntire K. R., Waldmann T. A., Hakala T. R., Fraley E. E. Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germ-cell testicular cancer. N Engl J Med. 1976 Nov 25;295(22):1237–1240. doi: 10.1056/NEJM197611252952207. [DOI] [PubMed] [Google Scholar]
- Quivey J. M., Fu K. K., Herzog K. A., Weiss J. M., Phillips T. L. Malignant tumors of the testis: analysis of treatment results and sites and causes of failure. Cancer. 1977 Mar;39(3):1247–1253. doi: 10.1002/1097-0142(197703)39:3<1247::aid-cncr2820390334>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
- Smithers D., Wallace E. N., Wallace D. M. Radiotherapy for patients with tumours of the testicle. Br J Urol. 1971 Feb;43(1):83–92. doi: 10.1111/j.1464-410x.1971.tb04938.x. [DOI] [PubMed] [Google Scholar]
- Williams C. Current dilemmas in the management of non-seminomatous germ cell tumors of the testis. Cancer Treat Rev. 1977 Dec;4(4):275–297. doi: 10.1016/s0305-7372(77)80003-0. [DOI] [PubMed] [Google Scholar]